Scarica l'app Stockscreener
519.57
0.48%
-2.48
Dopo l'orario di chiusura:
518.00
-1.57
-0.30%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TMO Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$522.05
Aprire:
$522.73
Volume 24 ore:
1.52M
Relative Volume:
0.84
Capitalizzazione di mercato:
$196.01B
Reddito:
$42.88B
Utile/perdita netta:
$6.34B
Rapporto P/E:
31.43
EPS:
16.53
Flusso di cassa netto:
$7.27B
1 W Prestazione:
-1.37%
1M Prestazione:
-2.31%
6M Prestazione:
-14.89%
1 anno Prestazione:
-11.06%
Intervallo 1D:
$514.67
$525.72
Intervallo di 1 settimana:
$508.35
$526.76
Portata 52W:
$493.30
$627.88
Thermo Fisher Scientific Inc Stock (TMO) Company Profile
Nome
Thermo Fisher Scientific Inc
Settore
Industria
Telefono
(781) 622-1000
Indirizzo
168 THIRD AVENUE, WALTHAM, MA
Confronta TMO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TMO
Thermo Fisher Scientific Inc
|
519.57 | 196.01B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
212.60 | 151.95B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
122.49 | 34.94B | 6.53B | 1.26B | 1.31B | 4.35 |
|
IDXX
Idexx Laboratories Inc
|
422.36 | 34.35B | 3.90B | 887.87M | 798.08M | 10.67 |
|
IQV
Iqvia Holdings Inc
|
184.90 | 32.60B | 15.41B | 1.37B | 2.11B | 7.50 |
Thermo Fisher Scientific Inc Stock (TMO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2024-12-23 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-14 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-01 | Iniziato | Stephens | Overweight |
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-03-18 | Ripresa | Citigroup | Neutral |
| 2024-01-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-01-08 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2023-12-18 | Iniziato | HSBC Securities | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-26 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-10-25 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-09-06 | Ripresa | Citigroup | Buy |
| 2023-07-19 | Iniziato | Raymond James | Outperform |
| 2023-07-19 | Reiterato | Robert W. Baird | Outperform |
| 2023-07-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2023-04-04 | Reiterato | Barclays | Overweight |
| 2022-12-14 | Iniziato | Deutsche Bank | Buy |
| 2022-12-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-10-27 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Neutral |
| 2022-04-25 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2022-01-26 | Ripresa | Barclays | Overweight |
| 2021-10-20 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-10-15 | Ripresa | Cowen | Outperform |
| 2021-08-05 | Ripresa | Credit Suisse | Outperform |
| 2021-07-16 | Iniziato | The Benchmark Company | Buy |
| 2021-03-18 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2021-03-03 | Iniziato | Barclays | Overweight |
| 2021-01-08 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2020-12-16 | Downgrade | Citigroup | Buy → Neutral |
| 2020-12-02 | Iniziato | Goldman | Buy |
| 2020-11-10 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2020-09-30 | Iniziato | Atlantic Equities | Overweight |
| 2020-09-14 | Iniziato | Morgan Stanley | Overweight |
| 2020-08-20 | Ripresa | JP Morgan | Overweight |
| 2020-07-15 | Aggiornamento | Cleveland Research | Neutral → Buy |
| 2020-07-07 | Reiterato | Needham | Buy |
| 2020-04-23 | Reiterato | Needham | Buy |
| 2020-01-31 | Reiterato | Needham | Buy |
| 2020-01-22 | Iniziato | Credit Suisse | Neutral |
| 2020-01-08 | Iniziato | Wells Fargo | Equal Weight |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-07-25 | Reiterato | Needham | Buy |
| 2019-07-16 | Downgrade | Needham | Strong Buy → Buy |
| 2019-05-30 | Iniziato | Wolfe Research | Outperform |
| 2019-05-23 | Reiterato | Needham | Strong Buy |
| 2019-04-22 | Reiterato | Needham | Strong Buy |
| 2019-04-16 | Reiterato | BofA/Merrill | Buy |
Mostra tutto
Thermo Fisher Scientific Inc Borsa (TMO) Ultime notizie
Is Thermo Fisher Scientific Inc. (TMO) the Best Strong Buy Stock to Buy Right Now? - Insider Monkey
Biotechnology Reagents and Kits Market A Comprehensive Study - openPR
Gas Chromatography Market Is Booming Worldwide 2025-2032 | - openPR
Thermo Fisher Scientific debuts Transcend VTLX-1 UHPLC system for automated sample preparation - R&D World
$100 Invested In Thermo Fisher Scientific 20 Years Ago Would Be Worth This Much Today - Benzinga
Is the Market Bullish or Bearish on Thermo Fisher Scientific? - Benzinga
Senior VP & General Counsel Michael Boxer Sold A Bunch Of Shares In Thermo Fisher Scientific - Simply Wall St
HSBC Adjusts Price Target on Thermo Fisher Scientific to $670 From $700, Keeps Buy Rating - Marketscreener.com
Layoff Tracker: GRO Biosciences Cuts Staff Amid Quest for Strategic Alternatives - BioSpace
Faces of HR: Thermo Fisher Scientific's Pallavi Srivastava on the importance of fungibility of skills within the workforce - Human Resources Online
New exhibit at Discovery Center showcases lab techniques for kids - MyStateline.com
Market Whales and Their Recent Bets on TMO Options - Benzinga
CRDMO Market Research 2025: A Highly Competitive $328 - GlobeNewswire
Exosomes Drug Market Detailed In New Research Report 2025 | Thermo Fisher Scientific, Inc., Bio-Techne - openPR
Thermo Fisher Scientific’s CHF1.425 Billion Bond Issuance - Global Legal Chronicle
Laboratory Equipment and Disposables Market is expected - openPR
Complement C4 Antibody Market Research 2025: Growing Focus on Precision Medicine and Targeted Therapies, and Increasing Investment in Immunotherapies and Biologic Drugs - GlobeNewswire Inc.
Ex-Dividend Reminder: Gilead Sciences, CONMED and Thermo Fisher Scientific - Nasdaq
Gas Chromatograph Market Industry Report 2025, with Profiles of Agilent, Shimadzu, Thermo Fisher Scientific, PerkinElmer, Shandong Huifen, Shanghai Kechuang, Zhejiang Fuli Analytical Instrument & BFRL - GlobeNewswire Inc.
Thermo Fisher Executive Cashes In on Stock Sale! - TipRanks
Thermo Fisher Scientific SVP sells $2.01 million in stock By Investing.com - Investing.com Australia
Thermo Fisher Scientific SVP sells $2.01 million in stock - Investing.com
Neurological Biomarkers: Global Market Review 2020-2024 and - GlobeNewswire
Neurological Biomarkers: Global Market Review 2020-2024 and Forecast to 2030, Featuring Analysis of PerkinElmer, Abbott Labs, Thermo Fisher Scientific, Banyan Biomarkers, Bio-Rad Labs & More - Yahoo Finance
Molecular Breeding Market Insights, Competitive Intelligence and Growth Forecast 2025-2030 - GlobeNewswire Inc.
Mexico In-Vitro Diagnostics Market Deep Research 2025-2032 | Thermo Fisher Scientific Inc., Siemens Healthineers - openPR
Thermo Fisher Scientific: Not Living Up To Its Positioning (NYSE:TMO) - Seeking Alpha
WilmerHale Advises Thermo Fisher on its CHF 1.425 Billion Offering of Bonds - WilmerHale
Cas Nuclease Market Size, Forecast 2031 by Key Companies- Thermo - openPR
Thermo Fisher Scientific Inc. to Host Earnings Call - ACCESS Newswire
Insider Selling: Thermo Fisher Scientific Inc. (NYSE:TMO) CEO Sells $5,166,700.00 in Stock - Defense World
A New Era of STEMOptimization for Advanced Materials Discovery - AZoM
Lung Cancer Diagnostics Market Forecast Report and - GlobeNewswire
Lung Cancer Diagnostics Market Forecast Report and Competitive Analysis 2025-2033 Featuring llumina, Abbott, Thermo Fisher Scientific, QIAGEN, Roche, Sanofi, Agilent Technologies, bioMerieux - Yahoo Finance
Unit Dose Manufacturing Industry Report 2025-2030: Market - GlobeNewswire
Unit Dose Manufacturing Industry Report 2025-2030: Market to Cross $150.6 Billion Led by Catalent, Unither Pharmaceuticals, and Thermo Fisher Scientific - Yahoo Finance
Thermo Fisher Scientific: Strong Q4, Strategic M&A, And Poised For Growth In Life Sciences - Seeking Alpha
Thermo Fisher Scientific CEO sells $9.3 million in stock By Investing.com - Investing.com South Africa
Thermo Fisher Scientific CEO sells $9.3 million in stock - Investing.com India
Here’s Why Thermo Fisher Scientific (TMO) Fell in Q4 - MSN
Deutsche Bank Adjusts Price Target on Thermo Fisher Scientific to $615 From $630, Keeps Buy Rating - Marketscreener.com
Multiplex Assay Market Generated Opportunities, Future Scope - openPR
Thermo Fisher Scientific Inc. stock rises Wednesday, outperforms market - MarketWatch
Ryan Snyder On AI And Digital Innovation At Thermo Fisher Scientific - Forbes
Invest with Confidence: Intrinsic Value Unveiled of Thermo Fisher Scientific Inc - Yahoo Finance
Thermo Fisher Scientific EVP Michael Shafer sells $945,037 in stock - Investing.com
Thermo Fisher Scientific EVP Michael Shafer sells $945,037 in stock By Investing.com - Investing.com UK
Thermo Fisher Scientific Inc. (TMO): A Bull Case Theory - Insider Monkey
Assessment of the $1.41 Billion Peptide Synthesis Industry - GlobeNewswire
Assessment of the $1.41 Billion Peptide Synthesis Industry 2025-2029: Dominated by Bachem, Thermo Fisher Scientific, Merck, GenScript, and CEM Corporation - Yahoo Finance
Global Microbiological Testing of Water Market to Reach $2.3 Billion by 2027, Dominated by Tech Giants 3M - EIN News
Thermo Fisher Scientific Inc Azioni (TMO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.88%
0.16%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):